Although CD11b+-cells exposed to EDA-FN enhanced cancer growth, use of cKO CD11b+-cells or cells treated with the α5β1 inhibitor or the arginase inhibitor together with EDA-FN showed diminished or normal growth (Figs 9B, 9C and 10). Here, ITGAM is linked to cancer.